The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Amanj Baker, Li-Chia Chen, Rachel A. Elliott, Brian Godman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.
LanguageEnglish
Article number367
Number of pages15
JournalBMC Health Services Research
Volume15
DOIs
Publication statusPublished - 10 Sep 2015

Fingerprint

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Primary Health Care
Research Design
Hypertension
Cost Savings
National Health Programs
Costs and Cost Analysis

Keywords

  • better care better value
  • angiotensin-converting enzyme inhibitors
  • angiotensin receptor blockers
  • cardiovascular disease
  • hypertension
  • pharmacoeconomics

Cite this

@article{6d9ce576b411470b88c2e69e83b31032,
title = "The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design",
abstract = "In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 {\%} ACEIs/20 {\%} ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.",
keywords = "better care better value, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular disease, hypertension, pharmacoeconomics",
author = "Amanj Baker and Li-Chia Chen and Elliott, {Rachel A.} and Brian Godman",
year = "2015",
month = "9",
day = "10",
doi = "10.1186/s12913-015-1013-y",
language = "English",
volume = "15",
journal = "BMC Health Services Research",
issn = "1472-6963",

}

TY - JOUR

T1 - The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

AU - Baker, Amanj

AU - Chen, Li-Chia

AU - Elliott, Rachel A.

AU - Godman, Brian

PY - 2015/9/10

Y1 - 2015/9/10

N2 - In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.

AB - In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.

KW - better care better value

KW - angiotensin-converting enzyme inhibitors

KW - angiotensin receptor blockers

KW - cardiovascular disease

KW - hypertension

KW - pharmacoeconomics

UR - http://www.biomedcentral.com/1472-6963/15/367/abstract

U2 - 10.1186/s12913-015-1013-y

DO - 10.1186/s12913-015-1013-y

M3 - Article

VL - 15

JO - BMC Health Services Research

T2 - BMC Health Services Research

JF - BMC Health Services Research

SN - 1472-6963

M1 - 367

ER -